Evaluating Lead Bioavailability Data by Means of a Physiologically Based Lead Kinetic Model

A method of bioavailability estimation is presented in whicha physiologically based kinetic model of lead kinetics is fitsimultaneously to blood and bone lead concentrations after aperiod of exposure to dietary lead. Optimization of the simultaneousfit, varying only fractional absorption, gives the best estimateof fractional bioavailability for each treatment group. Theanalysis was applied to data from three separate studies inwhich rats were fed for 30 consecutive days purified diets containinglead added as lead acetate, mine waste-contaminated test soils,or mine waste itself. Fractional absorption decreased as leadintake increased, regardless of the source of the lead; butthe magnitude of this dose dependence was lead source-dependent.There were no differences in lead absorption by male and femalerats when lead intake was expressed per unit body weight. Fractionalabsorption varied from 4 to 5%, at low exposure rates (1–2mg lead/kg/day) when lead acetate was added to the diet, to0.24% at a high exposure rate (24 mg/kg/day) when a mine waste-contaminatedtest soil was added to the diet. Comparison of the results ofthis analysis with the results of a more conventional analysis,in which the bone and blood lead concentrations were separatelycompared with bone and blood lead concentrations in rats givendaily injections of lead acetate intravenously for 29 consecutivedays, demonstrated that the standard analysis failed to revealthe dose dependence of fractional absorption.     

OVERALL LONG-TERM IMPACT OF TOTAL HIP AND KNEE JOINT REPLACEMENT SURGERY ON PATIENTS WITH OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS

All patients with OA or RA entering an orthopaedic waiting listfor total hip or knee replacement surgery over a period of 2.5yr were prospectively assessed for overall pain (Visual AnalogueScale) and disability (Health Assessment Questionnaire) priorto and following their operation at annual intervals for upto 5 yr. A total of 293 patients had 335 operations (OA, hip164; OA, knee 76; RA, hip 41; RA, knee 54). A few patients (14)showed a deterioration in pain and function 1 yr after surgery,but the remainder showed improvements which took 1 yr or moreto reach maximum and were maintained for at least 3 yr. Althoughgreater for OA hip patients, improvements occurred and weremaintained in all groups, in spite of the polyarticular natureof RA. KEY WORDS: Osteoarthritis, Rheumatoid arthritis, Surgery, Outcome, Operation     

LC-MS/MS测定人血浆中对乙酰氨基酚及其人体药动学和生物等效性研究

目的 建立一种快速、灵敏的高效液相色谱-串联质谱（HPLC-MS/MS）方法以测定人血浆中对乙酰氨基酚浓度,并应用于两种对乙酰氨基酚制剂的人体药代动力学和生物等效性研究。方法 以替硝唑为内标,200μL血浆样品经5倍于其体积的乙酸乙酯液液萃取,再经Waters XBridge? C18柱等度洗脱分离后导入串联质谱,以正离子多反应监测模式进行定量分析,对乙酰氨基酚和内标的选择性反应离子对分别是m/z 152→110和248→121。方法经验证后应用于19名健康受试者单剂量空腹口服两种对乙酰氨基酚制剂500mg后药代动力学和生物等效性的研究。结果 血浆中对乙酰氨基酚在0.1～8.0 μg·mL-1范围内线性良好（r2 > 0.99）,最低检测限为 0.1 μg·mL-1,提取回收率为91.0%～98.7%,日内和日间准确度分别为98.8%～111.3% （精密度：CV ? 9.03%）和94.9%～102.6% （精密度：CV ? 10.68%）。生物等效性试验中,受试制剂与参比制剂的主要药代动力学参数Cmax、AUC0-t和AUC0-∞ 几何均值比的90%置信区间分别为83.50%～105.79%,94.25%～101.54%和93.24%～101.02%,均落在生物等效可接受标准80.00%～125.00%范围内。结论 所建立测定人血浆中对乙酰氨基酚浓度的HPLC-MS/MS法具有快速灵敏、回收率高、选择性好的特点,适用于对乙酰氨基酚片人体药代动力学和生物等效性研究。受试制剂与参比制剂在人体内吸收速度和程度相似,两种制剂生物等效。